Pacira BioSciences
PCRX
PCRX was delisted on the 16th of November, 2026.
258 hedge funds and large institutions have $1.15B invested in Pacira BioSciences in 2026 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 94 increasing their positions, 85 reducing their positions, and 25 closing their positions.
263% more call options, than puts
Call options by funds: $872K | Put options by funds: $240K
74% more capital inflows, than outflows
Capital inflows: $119M | Capital outflows: $68.4M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
36% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 25
11% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 85
3.48% more ownership
Funds ownership: 111.68% → 115.16% (+3.5%)
2% more funds holding
Funds holding: 254 → 258 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$12.7M |
| 2 |
LSV Asset Management
Chicago,
Illinois
|
+$11.7M |
| 3 |
Two Sigma Investments
New York
|
+$7.59M |
| 4 |
BlackRock
New York
|
+$5.82M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$4.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$5.97M |
| 2 |
Coppell Advisory Solutions
Coppell,
Texas
|
-$5.59M |
| 3 |
Easterly Investment Partners
Beverly,
Massachusetts
|
-$4.6M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$4.25M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.75M |
PCRX Hedge Fund Activity: Q3 2026 in Review
258 of the 8,220 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q3 2026, worth a combined $1.15B — up 2.9% from $1.12B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new PCRX positions and 25 closed out — a net gain of 9 holders — while 94 added to existing stakes and 85 trimmed.
The largest buyer was Jacobs Levy Equity Management, adding an estimated $12.7M. The largest seller was Millennium Management, exiting entirely with an estimated $5.97M sold.
- 258 institutional investors held Pacira BioSciences (PCRX) as of Q3 2026, up from 254 in Q2 2026.
- Funds reported $1.15B of Pacira BioSciences stock for Q3 2026, up 2.9% quarter-over-quarter.
- 34 funds opened new Pacira BioSciences positions in Q3 2026 and 25 closed out, a net change of +9 holders.
- The largest Pacira BioSciences buyer in Q3 2026 was Jacobs Levy Equity Management, an estimated $12.7M added.
- The largest Pacira BioSciences seller in Q3 2026 was Millennium Management, an estimated $5.97M sold.
Based on aggregated 13F filings for Q3 2026.